MedTrace Logo

Cancer-associated Gene Mutations in CML Treatment With TKIs by NGS

NCT04274231 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-04-12

No results posted yet for this study

Summary

We performed targeted-capture sequencing of 127 known and putative cancer-related genes of patients who best effect to TKIs ,or intolerance to TKIs,or resistance to TKIs by next-generation sequencing (NGS) .

Conditions

  • Different Gene Between Different TKIs Effection

Interventions

GENETIC

different effection

Analysis of the reasons for treatment

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • H Nanfang · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-16
Primary Completion
2022-12-01
Completion
2022-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04274231 on ClinicalTrials.gov